null - FindTrial

N/A - XELADYS

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-004211-23-FR

Enrollment

Registered

2011-10-04

Start date

2011-11-08

Completion date

Unknown

Last updated

2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.0 Level: PT Classification code 10043118 Term: Tardive dyskinesia System Organ Class: 10029205 - Nervous system disorders

Interventions

Trade Name: XENAZINE Product Name: XENAZINE Pharmaceutical Form: Buccal tablet CAS Number: 58-46-8 Other descriptive name: TETRABENAZINE Concentration unit: mg milligram(s) Concentration type: range C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 54 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

France

Contacts

Public ContactLoïc Fin

CHU Amiens

fin.loic@chu-amiens.fr33322668000

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026